GSK on NYSE

GSK

Logo: gsk.com4

British pharmaceutical and biotechnology company

GSK plc (an abbreviation of its former name GlaxoSmithKline plc) is a British multinational pharmaceutical and biotechnology company. It was established in 2000 by a merger of Glaxo Wellcome and SmithKline Beecham, which was itself a merger of a number of pharmaceutical companies around the Smith, Kline & French firm.3 From Wikipedia, CC BY-SA 4.0

Price unavailable

Last updated Oct 16, 2026.

Overview

32.7BRevenue, fiscal 20255
6.3BNet income, fiscal 20255
Dec 27, 2000Founded1

Compare with another stock.

  • TickerGSK on NYSE1
  • Industrybiotechnology, pharmaceutical industry1
  • HeadquartersLondon1
  • Founded inLondon1
  • Websitewww.gsk.com
  • Legal formpublic limited company1
  • Listed onLondon Stock Exchange (GSK), New York Stock Exchange (GSK)1
  • Incorporated inUnited Kingdom6
  • Business address79 New Oxford Street, London, Wc1A 1Dg6
  • Filer categoryLarge accelerated filer6
GlaxoSmithKline Headquarters on the Great West Road in Brentford - panoramio
Photo: Maxwell Hamilton, CC BY-SA 3.0, via Wikimedia Commons7

GSK plc (an abbreviation of its former name GlaxoSmithKline plc) is a British multinational pharmaceutical and biotechnology company. It was established in 2000 by a merger of Glaxo Wellcome and SmithKline Beecham, which was itself a merger of a number of pharmaceutical companies around the Smith, Kline & French firm. It is headquartered in London, England.3

Financials

From the company’s reports to the SEC. Every number links to the filing it came from. Figures are in GBP, the currency the company reports in.

Key numbers, fiscal 2025

72.4%Gross margin5
24.3%Operating margin5
19.3%Net margin5
4.1%Revenue growth, 20255
39.4%Return on equity5
6.4B GBPFree cash flow5

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Other costs81¢26.4B GBP
  • Profit19¢6.3B GBP

Out of 32.7B GBP in revenue.5

Where each dollar of operating cash went, fiscal 2025

  • Capital spending17¢1.3B GBP
  • Kept or used elsewhere83¢6.4B GBP

Out of 7.7B GBP of cash from operations.5

Financial statements

Revenue89101112532.7B GBP in 2025+6% since 2018
010.0B GBP20.0B GBP30.0B GBP40.0B GBP2018: 30.8B GBP30.8B GBP20182019: 33.8B GBP33.8B GBP2019+10%2020: 24.4B GBP24.4B GBP2020−28%2021: 24.7B GBP24.7B GBP2021+1%2022: 29.3B GBP29.3B GBP2022+19%2023: 30.3B GBP30.3B GBP2023+3%2024: 31.4B GBP31.4B GBP2024+3%2025: 32.7B GBP32.7B GBP2025+4%
Gross profit89101112523.6B GBP in 2025+15% since 2018
010.0B GBP20.0B GBP30.0B GBP2018: 20.6B GBP20.6B GBP20182019: 21.9B GBP21.9B GBP2019+6%2020: 16.4B GBP16.4B GBP2020−25%2021: 16.5B GBP16.5B GBP2021+1%2022: 19.8B GBP19.8B GBP2022+20%2023: 21.8B GBP21.8B GBP2023+10%2024: 22.3B GBP22.3B GBP2024+3%2025: 23.6B GBP23.6B GBP2025+6%
Operating income8910111257.9B GBP in 2025+45% since 2018
02.0B GBP4.0B GBP6.0B GBP8.0B GBP2018: 5.5B GBP5.5B GBP20182019: 7.0B GBP7.0B GBP2019+27%2020: 6.0B GBP6.0B GBP2020−14%2021: 4.4B GBP4.4B GBP2021−27%2022: 6.4B GBP6.4B GBP2022+48%2023: 6.7B GBP6.7B GBP2023+5%2024: 4.0B GBP4.0B GBP2024−40%2025: 7.9B GBP7.9B GBP2025+97%
Net income8910111256.3B GBP in 2025+55% since 2018
05.0B GBP10.0B GBP15.0B GBP20.0B GBP2018: 4.0B GBP4.0B GBP20182019: 5.3B GBP5.3B GBP2019+30%2020: 6.4B GBP6.4B GBP2020+21%2021: 5.1B GBP5.1B GBP2021−20%2022: 15.6B GBP15.6B GBP2022+207%2023: 5.3B GBP5.3B GBP2023−66%2024: 3.0B GBP3.0B GBP2024−44%2025: 6.3B GBP6.3B GBP2025+113%

Every line of the income statement in the latest annual report, as filed.5

Period ending2025-12-312024-12-312023-12-31
Turnover32.7B GBP31.4B GBP30.3B GBP
Cost of sales-9.0B GBP-9.0B GBP-8.6B GBP
Gross profit23.6B GBP22.3B GBP21.8B GBP
Selling, general and administration-9.1B GBP-11.0B GBP-9.4B GBP
Research and development-7.5B GBP-6.4B GBP-6.2B GBP
Royalty income879.0M GBP639.0M GBP953.0M GBP
Other operating income/(expense)16.0M GBP-1.5B GBP-363.0M GBP
Operating profit7.9B GBP4.0B GBP6.7B GBP
Finance income169.0M GBP122.0M GBP115.0M GBP
Finance expense-701.0M GBP-669.0M GBP-792.0M GBP
Share of after tax profit/(loss) of associates and joint ventures1.0M GBP-3.0M GBP-5.0M GBP
Profit/(loss) on disposal of interests in associates and joint ventures0 GBP6.0M GBP1.0M GBP
Profit before taxation7.4B GBP3.5B GBP6.1B GBP
Taxation-1.1B GBP-526.0M GBP-756.0M GBP
Profit after taxation6.3B GBP3.0B GBP5.3B GBP
Profit attributable to non-controlling interests573.0M GBP376.0M GBP380.0M GBP
Profit attributable to shareholders5.7B GBP2.6B GBP4.9B GBP
Basic earnings per share (pence) (in pence per share)1.41 GBP0.63 GBP1.22 GBP
Diluted earnings per share (pence) (in pence per share)1.39 GBP0.62 GBP1.20 GBP

Compare GSK with another company

How it started

Glaxo

Joseph Nathan and Co. was founded in 1873, as a general trading company in Wellington, New Zealand, by a Londoner, Joseph Edward Nathan. In 1904, it began producing a dried-milk baby food from excess milk produced on dairy farms near Bunnythorpe. The resulting product was first known as Defiance, then as Glaxo (cf. Greek galaxias, "milky"), and was sold with the slogan "Glaxo builds bonnie babies." The Glaxo Laboratories sign is still visible on what is now a car repair shop on the main street of Bunnythorpe. The company's first pharmaceutical product, released in 1924, was vitamin D.

Glaxo Laboratories was incorporated as a distinct subsidiary company in London in 1935. Joseph Nathan's shareholders reorganised the group's structure in 1947, making Glaxo the parent and obtained a listing on the London Stock Exchange. Glaxo acquired Allen & Hanburys in 1958. The Scottish pharmacologist David Jack was hired as a researcher for Allen & Hanburys a few years after Glaxo took it over; he went on to lead the company's research and development (R&D) until 1987. After Glaxo bought Meyer Laboratories in 1978, it began to play an important role in the US market. In 1983, the American arm, Glaxo Inc., moved to Research Triangle Park (US headquarters/research) and Zebulon (US manufacturing) in North Carolina.

Burroughs Wellcome

Burroughs Wellcome & Company was founded in 1880, in London by the American pharmacists Henry Wellcome and Silas Burroughs. The Wellcome Tropical Research Laboratories opened in 1902. In the 1920s, Burroughs Wellcome established research and manufacturing facilities in Tuckahoe, New York, which served as the US headquarters until the company moved to Research Triangle Park in North Carolina in 1971. The Nobel Prize winning scientists Gertrude B. Elion and George H. Hitchings worked there and invented drugs still used many years later, such as mercaptopurine. In 1959, the Wellcome Foundation bought Cooper, McDougall & Robertson Inc to become more active in animal health.

When Burroughs Wellcome decided to move its headquarters, the company selected Paul Rudolph to design its new building. The Elion-Hitchings Building "was celebrated worldwide when it was built," according to Paul Rudolph Heritage Foundation president Kelvin Dickinson. Alex Sayf Cummings of Georgia State University wrote in 2016, that the "iconic building helped define the image of RTP," saying, "Love it or hate it, Rudolph's design remains an impressively audacious creative gesture and an important part of the history of both architecture and Research Triangle Park." United Therapeutics, which bought the building in 2012, announced plans in 2020, to tear it down.

From Wikipedia’s article on GSK, shared under CC BY-SA 4.0.3

Leadership

Who has led GSK, and when. Pick a name to see everywhere that person has worked.

Board members and other officers (2)

Products and brands

  • medication

Listed on Wikidata.1

Subsidiaries and ownership

Subsidiaries

  • Glaxo SmithKline Korea Inc.
  • GlaxoSmithKline
  • GlaxoSmithKline
  • GlaxoSmithKline (Australia)
  • GlaxoSmithKline (Belgium)
  • GlaxoSmithKline (Canada)
  • GlaxoSmithKline (Croatia)
  • GlaxoSmithKline (France)
  • GlaxoSmithKline (Germany)
  • GlaxoSmithKline (Ireland)
  • GlaxoSmithKline (Italy)
  • GlaxoSmithKline (Poland)
  • GlaxoSmithKline (Sri Lanka)
  • GlaxoSmithKline (United States)
  • GlaxoSmithKline Algeria
  • GlaxoSmithKline Biologicals Dresden
  • GlaxoSmithKline Pharmaceuticals
  • GlaxoSmithKline Turkey
  • Sirtris Pharmaceuticals
  • Stiefel Laboratories
  • GlaxoSmithKline Biologicals since 2000

Also owns

  • Aquafresh
  • Eno
  • Nicorette
  • Sensodyne

From Wikidata.1

Acquisitions

  1. 2000Acquired GlaxoSmithKline Biologicals1
  2. Succeeded Glaxo Wellcome1
  3. Succeeded SmithKline Beecham1
  4. Succeeded Block Drug1

Employees over time

  • 201699,3001
  • 201399,5411

Former names

  • GLAXOSMITHKLINE PLCMay 14, 2001 to May 16, 20226

Timeline

  1. Apr 2017New chief executive Emma Walmsley becomes CEO1
  2. May 21, 2008New chief executive Andrew Witty becomes CEO1
  3. Dec 27, 2000Founded Founded in London1
  4. Dec 2000New chief executive Jean-Pierre Garnier becomes CEO1

Recent filings

  1. Oct 14, 20266-K DIRECTOR/PDMR SHAREHOLDING
  2. Oct 13, 20266-K DIRECTOR/PDMR SHAREHOLDING
  3. Oct 13, 20266-K DIRECTOR/PDMR SHAREHOLDING
  4. Oct 13, 2026S-8
  5. Oct 8, 20266-K WENDY BECKER CBE - NEW DIRECTORSHIP
  6. Oct 6, 20266-K ADMISSION TO TRADING
  7. Oct 1, 20266-K TOTAL VOTING RIGHTS
  8. Sep 24, 20266-K DIRECTOR/PDMR SHAREHOLDING
  9. Sep 22, 20266-K DIRECTOR/PDMR SHAREHOLDING
  10. Sep 22, 2026CERT NYSE CERTIFICATION
  11. Sep 15, 20266-K GSK TO ACQUIRE T CELL-ENGAGER FOR MULTIPLE MYELOMA
  12. Sep 15, 20266-K
  13. Sep 15, 20268-A12B
  14. Sep 14, 20266-K JIDEYTRO POSITIVE DATA FOR ROS1-POSITIVE NSCLC
  15. Sep 14, 20266-K RIS-REZ POSITIVE PH 3 OS LUNG CANCER DATA IN CHINA

Every filing from the last three years, summarized. The full record is on SEC EDGAR.2

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
    Company websiteGSK logo
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13